A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects
Status:
Completed
Trial end date:
2019-08-04
Target enrollment:
Participant gender:
Summary
This study is being done to compare the pharmacokinetics (PK) and safety/tolerability of
tucatinib in healthy Japanese and Caucasian participants.
Three cohorts of healthy Japanese and Caucasian men and women will be admitted to the
Clinical Research Unit (CRU) and receive multiple oral doses of tucatinib over 14 days with
and without food.
Subjects will be in the study for up to 45 days, including the screening period.
Due to practical considerations, each cohort will be dosed sequentially (this is not a dose
escalation study).